Vicore Pharma Q3 operating loss widens 15% to SEK 133.3 million
Bitget2026/11/05 07:08- Vicore Pharma’s third-quarter 2026 loss for the period widened 10% year over year to SEK 124.3 million.
- Net revenues fell 25% year over year to SEK 600,000.
- Cash, cash equivalents and short-term investments totaled SEK 772 million at September 30, 2026, down 34% from December 31, 2025.
- In October, independent monitors recommended continuing the Phase 2b ASPIRE trial of buloxibutid without modification following a planned futility analysis.
- ASPIRE topline results remain expected in mid-2027, with preparations advancing for a potential Phase 3 trial.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Tesla (TSLA.US) drops over 10% in a week, but ARK keeps buying! Cathie Wood: This is the moment we've been waiting for
Despite the recent volatility in Tesla's stock price, ARK Invest founder Cathie Wood, known as the "Goddess of Wall Street," remains optimistic about the company.
U.S. stock futures fluctuate by $650 billions due to news related to Jensen Huang
Nikkei Average Index gains expand to 2.78%
Surprise! Japan intervened in the forex market three times this summer, selling a record 154 trillion yen in three days
Japan has confirmed that it intervened in the foreign exchange market three times this summer, buying yen to support the exchange rate, corroborating earlier market reports. This included the first joint intervention with the United States to support the yen in nearly thirty years.
Crypto prices
More
